Country
Full text data for US and EP
Status
Type
Filing Date
Publication Date
Inventor
Assignee
Click to expand
IPC
No.
Publication Number
Title
Publication/Patent Number Publication/Patent Number
Publication date Publication date
Application number Application number
Filing date Filing date
Inventor Inventor
Assignee Assignee
IPC IPC
1
US10040836B2
Publication/Patent Number: US10040836B2
Publication date: 2018-08-07
Application number: 15/404,378
Filing date: 2017-01-12
Abstract: An isolated peptide comprising a Huntingtin (Htt) amino acid sequence being no longer than 15 amino acids, wherein said Htt amino acid sequence comprises the sequence X1X2X3X4 X5, wherein X1 is a hydrophobic amino acid or threonine, X2 is a hydrophobic amino acid, X3 is a hydrophobic amino acid, X4 is an acidic amino acid and X5 is selected from the group consisting of glycine, serine and alanine, the peptide capable of specifically inhibiting the activity of caspase 6. An isolated peptide comprising a Huntingtin (Htt) amino acid sequence being no longer than 15 amino acids, wherein said Htt amino acid sequence comprises the sequence X1X2X3X4 X5, wherein X1 is a hydrophobic amino acid or threonine, X2 is a hydrophobic amino acid, X3 is a ...more ...less
2
US10040840B2
Publication/Patent Number: US10040840B2
Publication date: 2018-08-07
Application number: 15/281,795
Filing date: 2016-09-30
Abstract: Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair or regenerate damaged or diseased tissue.
3
US10040843B2
Publication/Patent Number: US10040843B2
Publication date: 2018-08-07
Application number: 15/140,414
Filing date: 2016-04-27
Abstract: The present invention generally relates to fusion proteins of antibodies and interleukin-10 (IL-10). In addition, the present invention relates to polynucleotides encoding such fusion proteins, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the fusion proteins of the invention, and to methods of using them in the treatment of disease. The present invention generally relates to fusion proteins of antibodies and interleukin-10 (IL-10). In addition, the present invention relates to polynucleotides encoding such fusion proteins, and vectors and host cells comprising such polynucleotides. The invention further ...more ...less
4
US10040844B2
Publication/Patent Number: US10040844B2
Publication date: 2018-08-07
Application number: 14/920,816
Filing date: 2015-10-22
Abstract: The invention described herein features methods of isolating monoclonal antibodies or polypeptides that bind to a cell surface expressed antigen. The method of catch and release utilizes engineered protease site for cleavage antigen-antibody or antigen-polypeptide complexes. In some embodiments the protease cleavage site to cleave the complexes is an exogenous protease to mammalian cell. In various embodiments the protease cleavage site to cleave the complexes is an endogenous protease to mammalian cell. The invention described herein features methods of isolating monoclonal antibodies or polypeptides that bind to a cell surface expressed antigen. The method of catch and release utilizes engineered protease site for cleavage antigen-antibody or antigen-polypeptide complexes. In ...more ...less
5
US10040851B2
Publication/Patent Number: US10040851B2
Publication date: 2018-08-07
Application number: 14/968,098
Filing date: 2015-12-14
Inventor: Smith, Jeffrey T. L.  
Abstract: The present invention is directed to therapeutic methods using IL-6 antagonists such as antibodies and fragments thereof having binding specificity for IL-6 to improve survivability or quality of life of a patient in need thereof. In preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level or a reduced serum albumin level prior to treatment. In another preferred embodiment, the patient's Glasgow Prognostic Score will be increased and survivability will preferably be improved. The present invention is directed to therapeutic methods using IL-6 antagonists such as antibodies and fragments thereof having binding specificity for IL-6 to improve survivability or quality of life of a patient in need thereof. In preferred embodiments these patients will ...more ...less
6
US10040854B2
Publication/Patent Number: US10040854B2
Publication date: 2018-08-07
Application number: 14/397,074
Filing date: 2013-04-24
Abstract: The invention provides an antibody or fragment thereof that specifically binds to human endothelial vascular cell adhesion molecule-1 (VCAM-1), wherein the antibody or fragment thereof binds to the extracellular domain of VCAM-1, and wherein the antibody or fragment thereof binds to VCAM-1 when expressed on endothelial cells, wherein the antibody or fragment thereof is a human or humanized antibody, or fragment thereof. The invention provides an antibody or fragment thereof that specifically binds to human endothelial vascular cell adhesion molecule-1 (VCAM-1), wherein the antibody or fragment thereof binds to the extracellular domain of VCAM-1, and wherein the antibody or fragment thereof ...more ...less
7
US10040858B2
Publication/Patent Number: US10040858B2
Publication date: 2018-08-07
Application number: 14/976,346
Filing date: 2015-12-21
Abstract: Methods of treating pigmented villonodular synovitis (PVNS) with antibodies that bind colony stimulating factor 1 receptor (CSF1R) are provided.
8
US10040861B2
Publication/Patent Number: US10040861B2
Publication date: 2018-08-07
Application number: 15/381,205
Filing date: 2016-12-16
Abstract: Among N-glycoside-linked sugar chains which are bound to the Fc region of an antibody, sugar chains which are bound to Asn at position 297 relates to the activity and stability of the antibody in blood, but there is a possibility that extra sugar chains bound to the amino acid residues at positions other than 297 have influences upon the antibody constant region-mediated activity and a possibility of causing a problem of uniformity as a therapeutic antibody preparation. Accordingly, among N-glycoside-linked sugar chains which bind to the Fc region of the antibody, a method for controlling extra sugar chains which are bound to Asn residues at positions other than position 297 according to the EU index is required. The present invention provides an antibody variant composition, comprising amino acid residues of an Asn-X-Ser/Thr (X represents an amino acid residue other than Pro) sequence at positions other than positions 297 to 299 according to the EU index in an Fc region of a human IgG antibody, in which at least one amino acid substitution selected from an amino acid substitution of Asn to other amino acid residue, an amino acid substitution of X to Pro and an amino acid substitution of Ser/Thr to other amino acid residue is carried out, and a fragment of the antibody variant composition. Among N-glycoside-linked sugar chains which are bound to the Fc region of an antibody, sugar chains which are bound to Asn at position 297 relates to the activity and stability of the antibody in blood, but there is a possibility that extra sugar chains bound to the amino acid ...more ...less
9
US10040862B2
Publication/Patent Number: US10040862B2
Publication date: 2018-08-07
Application number: 15/303,720
Filing date: 2015-04-17
Abstract: Humanized or chimeric anti-CD99 monoclonal antibodies are provided. The antibodies bind to and neutralize human CD99, and find use in various therapeutic methods. Embodiments of the invention include isolated antibodies and derivatives and fragments thereof, pharmaceutical formulations comprising one or more of the humanized or chimeric anti-CD99 monoclonal antibodies; and cell lines that produce these monoclonal antibodies. Also provided are amino acid sequences of the antibodies. Humanized or chimeric anti-CD99 monoclonal antibodies are provided. The antibodies bind to and neutralize human CD99, and find use in various therapeutic methods. Embodiments of the invention include isolated antibodies and derivatives and fragments thereof, pharmaceutical ...more ...less
10
US10040864B2
Publication/Patent Number: US10040864B2
Publication date: 2018-08-07
Application number: 15/908,221
Filing date: 2018-02-28
Inventor: Harding, Fiona A.  
Abstract: The present disclosure provides novel anti-OX40 antibodies, compositions including the antibodies, nucleic acids encoding the antibodies, and methods of making and using the same.
11
US10040873B2
Publication/Patent Number: US10040873B2
Publication date: 2018-08-07
Application number: 14/653,362
Filing date: 2013-12-19
Abstract: This invention discloses a sulfur free and ZnO free cross-linking composition comprising a multifunctional phosphine crosslinking agent and halobutyl polymers or halogen containing polymers.
12
US10040877B2
Publication/Patent Number: US10040877B2
Publication date: 2018-08-07
Application number: 14/378,193
Filing date: 2013-01-22
Inventor: Washizu, Kensuke  
Abstract: A pneumatic tire produced by processing a rubber composition including a hydrogenated branched conjugated diene copolymer produced by copolymerizing a branched conjugated diene compound and a vinyl compound to form a branched conjugated diene copolymer and hydrogenating the branched conjugated diene copolymer. The branched conjugated diene compound is represented by formula (1), where R1 is an aliphatic hydrocarbon having 6 to 11 carbon atoms, the vinyl compound is represented by formula (3), where R4 is a hydrogen atom, an aliphatic hydrocarbon group having 1 to 3 carbon atoms, an alicyclic hydrocarbon group having 3 to 8 carbon atoms, or an aromatic hydrocarbon group having 6 to 10 carbon atoms, copolymerization ratio of the branched conjugated diene compound is 1 to 99% by weight, copolymerization ratio of the vinyl compound is 99 to 1% by weight, the branched conjugated diene compound is myrcene and/or farnesene, and the vinyl compound is styrene. A pneumatic tire produced by processing a rubber composition including a hydrogenated branched conjugated diene copolymer produced by copolymerizing a branched conjugated diene compound and a vinyl compound to form a branched conjugated diene copolymer and hydrogenating the ...more ...less
13
US10040878B2
Publication/Patent Number: US10040878B2
Publication date: 2018-08-07
Application number: 15/101,803
Filing date: 2015-09-14
Assignee: LG CHEM, LTD.
Abstract: The present invention relates to a vinyl chloride polymer having good thermal stability due to the restraint of dehydrochlorination by heat or ultraviolet rays, and a method of preparing the same. The generation of the dehydrochlorination of the vinyl chloride polymer due to heat or ultraviolet rays may be markedly restrained, the thermal stability thereof may be improved, and the discoloration thereof or the modification of the physical properties thereof may be prevented. In addition, a modifier may be introduced to a polymerization process at the end of the polymerization, and high thermal stability may be attained without generating the transformation of the vinyl chloride polymer. The present invention relates to a vinyl chloride polymer having good thermal stability due to the restraint of dehydrochlorination by heat or ultraviolet rays, and a method of preparing the same. The generation of the dehydrochlorination of the vinyl chloride polymer due to ...more ...less
14
US10040880B2
Publication/Patent Number: US10040880B2
Publication date: 2018-08-07
Application number: 14/653,941
Filing date: 2013-12-20
Abstract: The present invention relates to an article consisting of or comprising a bidirectional shape-memory polymer (bSMP), the bSMP comprising: first phase-segregated domains (AD) having a first transition temperature (Tt,AD) corresponding to a crystallization transition or glass transition of the first domains (AD), second phase-segregated domains (SD) having a second transition temperature (Tt,AD) corresponding to a crystallization transition or glass transition of the second domains (SD), the second transition temperature (Tt,SD) being higher than the first transition temperature (Tt,AD), and covalent or physical bonds cross-linking the polymer chains of the bSMP, and in this way interconnecting the first and second domains (AD, SD), wherein the second phase-separated domains (SD) form a skeleton which is at least partially embedded in the first phase-segregated domains (AD), and wherein polymer chain segments of the bSMP forming the first domains (AD) are substantially orientated in a common direction, such that the bSMP is able to undergo a reversible shape-shift between a first shape (A) at a first temperature (Thigh) and a second shape (B) at a second temperature (Tlow) upon variation of temperature between the first and second temperature (Thigh, Tlow) driven by the crystallization and melting or vitrification and melting of the first phase-separated domains (AD) and without application of an external stress, with Tlow<Tt,AD<Thigh<Tt,SD. The present invention relates to an article consisting of or comprising a bidirectional shape-memory polymer (bSMP), the bSMP comprising: first phase-segregated domains (AD) having a first transition temperature (Tt,AD) corresponding to a crystallization transition or glass ...more ...less